About MEAJO | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions to authors | Online submission | Subscribe | Advertise | Contact | Login 
Middle East African Journal of Ophthalmology Middle East African Journal of Ophthalmology
Users Online: 3324   Home Print this page Email this page Small font sizeDefault font sizeIncrease font size
ORIGINAL ARTICLE
Year : 2016  |  Volume : 23  |  Issue : 1  |  Page : 135-138

Tacrolimus ointment for treatment of vernal keratoconjunctivitis


1 Department of Ophthalmology, College of Medicine, King Khaled University, Abha, Saudi Arabia
2 Department of Ophthalmology, Aseer Central Hospital, Abha, Saudi Arabia
3 Department of Microbiology and Clinical Parasitology, College of Medicine, King Khaled University, Abha, Saudi Arabia

Correspondence Address:
Abdulrahman M Al-Amri
Department of Ophthalmology, College of Medicine, King Khaled University, P. O. Box 641, Abha 61421
Saudi Arabia
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0974-9233.164616

Rights and Permissions

Purpose: To evaluate the safety and efficacy of tacrolimus 0.1% ointment for the treatment of refractory vernal keratoconjunctivitis (VKC). Materials and Methods: This prospective, nonrandomized case series enrolled 20 patients (40 eyes) with severe VKC, who were treated with tacrolimus 0.1% ointment. The mean age of the patients was 18.25 ± 4.2 years (range, 9–31 years). Each patient completed a follow-up period of at least 24 months. The main outcome measure was the clinical response to treatment. Results: after starting treatment with topical tacrolimus. Treatment was gradually reduced, with increasing intervals between applications. VKC recurred in all patients who attempted to discontinue treatment. No additional medications were required and no significant changes in visual acuity or refraction were documented. Five patients discontinued treatment due to a severe burning sensation and were excluded from the study. Conclusions: Tacrolimus, 0.1% ointment, is a safe and effective treatment for VKC refractory to standard treatment and may be used as a substitute for steroid treatments used to controlled disease activity. However, adverse effects could cause poor patient compliance.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed4732    
    Printed235    
    Emailed0    
    PDF Downloaded293    
    Comments [Add]    

Recommend this journal